Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

PHASE1TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Advanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
Interventions
DRUG

MT-6402

Experimental Treatment

Trial Locations (16)

17325

Pennsylvania Cancer Specialists and Research Institute, Gettysburg

28078

Carolina BioOncology, Huntersville

29605

Prisma Health, Greenville

30265

Comprehensive Care and Research Center - Atlanta, Newnan

37203

Tennessee Oncology, PLLC, Nashville

40202

University of Louisville Health - Brown Cancer Center, Louisville

57104

Sanford Cancer Center, Sioux Falls

60099

Comprehensive Care and Research Center - Chicago, Chicago

63110

Washington University School of Medicine - St. Louis, St Louis

75230

Mary Crowley Cancer Research, Dallas

77024

Oncology Consultants, Houston

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

90033

USC Medical Center, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

91010

City of Hope Medical Center, Duarte

03766

Dartmouth Hitchcock, Lebanon

Sponsors
All Listed Sponsors
lead

Molecular Templates, Inc.

INDUSTRY